Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Promedior (Malvern, PA) a clinical stage biotechnology company developing pentraxin therapeutics for fibroproliferative diseases, closed a $21.5M Series D financing. Participants include Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.

Hookipa Biotech (Austria) a development-stage pharmaceutical company focused on prophylactic and therapeutic vaccines for viral diseases, closed $9.7M Series A financing. Participants include Sofinnova Partners and Forbion Capital Partners.

Oxyrane (Netherlands) a clinical-stage biopharmaceutical focused on enzyme replacement therapies for Pompe’s a lysosomal storage disease, closed a $26.5M Series D financing. Participants include Forbion Capital Partners, Morningside Group and New Science Ventures.

CircuLite (Saddle Brook, NJ) a clinical-stage medical device company focused on minimally invasive implantable devices for chronic heart failure, closed a $30M Series D financing. Participants include Forbion Capital Partners and MacAndrews & Forbes Holdings.

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

AM-Pharma (The Netherlands) a clinical-stage pharmaceutical company focused on acute kidney injury and ulcerative colitis, closed a $39.8M Series D financing. Participants include Ysios Capital Partners, Kurma Life Science Partners, Abbott Ventures, Shire Ventures, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.

Amakem (Belgium) a development-stage pharmaceutical company focused on glaucoma and other ophthalmic indications, closed a $25.3M Series A financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Vesalius BioCapital and Life Sciences Research Partners.

BlueBird Bio (Cambridge, MA) a clinical-stage developer of innovative stem cell-based gene therapies for severe genetic disorders, closed a $30M Series C financing. Participants include Arch Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group.

PneumRx (Mountain View, CA) a development-stage medical device company focused on improve lung function associated with emphysema, closed a $33M Series C financing. Participants include Forbion Capital Partners, Endeavour Vision, Adams Street Partners, Telegraph Hill Partners, Alta Partners, Spray Venture Partners and Leader Ventures.

Promedior (Malvern, PA) a clinical-stage biopharmaceutical company focused on inflammation and fibrotic disease, closed a $12M Series C financing. Participants include Forbion Capital Partners, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners and Easton Capital.

CicuLite (Saddle Brook, NJ) a clinical-stage medical device company focused on minimally invasive implantable devices for chronic heart failure, closed a $32.5M Series C financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Foundation Medical Partners and Oxford Bioscience Partners.

arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]

BioVex (Woburn, MA) a clinical-stage biologics company focused on metastatic melanoma, head and neck, pancreatic and colo-rectal cancer, closed a $30M Series F bringing the entire round to $70M. Participants have included Morningside Venture, Ventech, MVM Life Science Partners, Sectoral Asset Management, Ysios Capital Partners, Forbion Capital Partners, Credit Agricole Private Equity, Harris & Harris [...]

  

to top of page...